| Ataur Rehman, MD | |
|
901 Leighton Ave Ste 704, Anniston, AL 36207 | |
| (256) 240-7332 | |
| (256) 240-7334 |
| Full Name | Ataur Rehman |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 901 Leighton Ave Ste 704, Anniston, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770764201 | NPI | - | NPPES |
| 51545495 | Other | AL | BLUE CROSS BLUE SHIELD |
| 102389 | Medicaid | AL | |
| 009913761 | Medicaid | AL | |
| 51546945 | Other | AL | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 28235 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southerncare New Beacon Of Anniston | Anniston, AL | Hospice |
| Northeast Alabama Regional Medical Center | Anniston, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Health First Center Llc | 7810133071 | 2 |
News Archive
A protein known for helping cells withstand stress may also act as a switch that triggers free-swimming Schistosoma larvae to begin penetrating the skin and transforming into the parasitic flatworms that burden more than 240 million people worldwide with schistosomiasis.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
When temperatures throughout the sizzling Southwestern U.S. climb to over 100 degrees, the pavement can get hot enough to cause second-degree burns on human skin in a matter of seconds.
QIAGEN today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs.
› Verified 9 days ago
| Entity Name | Health First Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972843555 PECOS PAC ID: 7810133071 Enrollment ID: O20130415000334 |
News Archive
A protein known for helping cells withstand stress may also act as a switch that triggers free-swimming Schistosoma larvae to begin penetrating the skin and transforming into the parasitic flatworms that burden more than 240 million people worldwide with schistosomiasis.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
When temperatures throughout the sizzling Southwestern U.S. climb to over 100 degrees, the pavement can get hot enough to cause second-degree burns on human skin in a matter of seconds.
QIAGEN today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ataur Rehman, MD 901 Leighton Ave Ste 704, Anniston, AL 36207-5721 Ph: (256) 240-7332 | Ataur Rehman, MD 901 Leighton Ave Ste 704, Anniston, AL 36207 Ph: (256) 240-7332 |
News Archive
A protein known for helping cells withstand stress may also act as a switch that triggers free-swimming Schistosoma larvae to begin penetrating the skin and transforming into the parasitic flatworms that burden more than 240 million people worldwide with schistosomiasis.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
When temperatures throughout the sizzling Southwestern U.S. climb to over 100 degrees, the pavement can get hot enough to cause second-degree burns on human skin in a matter of seconds.
QIAGEN today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs.
› Verified 9 days ago
Dr. Rohit G Patel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 Keith Ave, Anniston, AL 36207 Phone: 256-236-8611 Fax: 256-236-8636 | |
Venugopala S Bheemanathini, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 522 E 11th St, Suite 200, Anniston, AL 36207 Phone: 256-237-5302 Fax: 256-237-5368 | |
Vishala Chindalore, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1010 Christine Ave, Anniston, AL 36207 Phone: 256-236-5631 Fax: 256-236-5637 | |
Dr. Chidiebere Maquincy Ibekwe, M.D, MPH, FACP Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 E 10th St, Anniston, AL 36207 Phone: 256-235-5639 | |
Wyndol Span Hamer Jr., M.D Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1700 Christine Ave, Suite 102, Anniston, AL 36207 Phone: 256-294-7004 Fax: 256-294-7005 | |
Almena Free, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 E 10th St, Anniston, AL 36207 Phone: 256-236-5631 Fax: 256-236-5335 | |
Mohamed Jasser, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 901 Leighton Ave, Suite 307, Anniston, AL 36207 Phone: 256-231-8636 Fax: 256-231-8684 |